Hotgen Biotech: Shunjing Pharmaceutical's SGT003 Completes First Subject Dosing in Phase I/IIa Trial

Hotgen Biotech announced that SGT003 Injection, independently developed by its controlling subsidiary Shunjing Pharmaceutical, is undergoing Phase I/IIa clinical research, and the first subject has recently completed enrollment and dosing.